Brunenders, a type I poliovirus (PV) strain, was developed in 1952 by J. F. Enders and colleagues through serial in vitro passaging of the parental Brunhilde strain, and was reported to display partial neuroattenuation in monkeys. This phenotype of attenuation encouraged two vaccine manufacturers to adopt Brunenders as the type I component for their inactivated poliovirus vaccines (IPVs) in the 1950s, although today no licensed IPV vaccine contains Brunenders. Here we confirmed, in a transgenic mouse model, the report of Enders on the reduced neurovirulence of Brunenders. Although dramatically neuroattenuated relative to WT PV strains, Brunenders remains more virulent than the attenuated oral vaccine strain, Sabin 1. Importantly, the neuroattenuation of Brunenders does not affect in vitro growth kinetics and in vitro antigenicity, which were similar to those of Mahoney, the conventional type I IPV vaccine strain. We showed, by full nucleotide sequencing, that Brunhilde and Brunenders differ at 31 nucleotides, eight of which lead to amino acid changes, all located in the capsid. Upon exchanging the Brunenders capsid sequence with that of the Mahoney capsid, WT neurovirulence was regained in vivo, suggesting a role for the capsid mutations in Brunenders attenuation. To date, as polio eradication draws closer, the switch to using attenuated strains for IPV is actively being pursued. Brunenders preceded this novel strategy as a partially attenuated IPV strain, accompanied by decades of successful use in the field. Providing data on the attenuation of Brunenders may be of value in the further construction of attenuated PV strains to support the grand pursuit of the global eradication of poliomyelitis.
INTRODUCTION
Poliovirus (PV) is a positive-sense RNA virus that can cause (paralytic) poliomyelitis in infected individuals. For protection against poliomyelitis, antibodies must be raised against each of the three antigenically distinct PV serotypes (types I, II and III), as they do not confer cross-protection against one another (Bodian et al., 1949) . Two effective vaccines against poliomyelitis have been available for over half a century. One is the oral poliovirus vaccine, a trivalent blend of the three live-attenuated Sabin 1, 2 and 3 strains. The other vaccine is the trivalent inactivated poliovirus vaccine (IPV) that was developed by Jonas Salk and consists of formalin-inactivated, WT, neurovirulent PVs, namely; Mahoney, MEF-1 and Saukett for types I, II and III, respectively. Upon developing his vaccine, Salk was aware of the fact that Mahoney was the most virulent type I strain he could use. However, he insisted on its use, as he observed the best immune response with Mahoney compared with other type I strains (Day, 2009; Offit, 2005) . Furthermore, he believed that complete inactivation abolished the risk of using a virulent vaccine strain. Some scientists disagreed with Salk at the time and therefore advocated the use of a less virulent virus as the basis for vaccine manufacture (Beale, 2011; Gear, 1956) , which was given further justification at the time after the Cutter incident. Here 380000 IPV doses that contained live, virulent PV due to inadequate inactivation during the manufacturing process at Cutter laboratories were administered to healthy children, with dramatic consequences (Offit, 2005) . Indeed, 40 000 children developed abortive paralytic poliomyelitis, 51 children remained permanently paralysed and five children died, all due to the type 1 Mahoney strain (Nathanson, 1963) . Root cause analysis revealed that the presence of cell debris during inactivation prevented sufficient interaction of the PVs with formaldehyde, resulting in non-inactivated viruses in the vaccine.
A few years before the Cutter incident, Enders et al. (1952) introduced the Brunenders strain and claimed its reduced pathogenicity compared with its parental Brunhilde strain, the type I prototype strain at the time, which was isolated from a chimpanzee after intranasal inoculation with pooled stool specimens from the Baltimore outbreak in 1939 (Bodian et al., 1949) . Enders' description of the derivation of the Brunenders strain is brief and undetailed, only describing 12 serial passages of the parental Brunhilde strain in suspensions of human embryonic skin muscle cell cultures (Enders et al., 1952) . Furthermore, limited literature and data are available on the characterization and reported attenuation of Brunenders, all stemming from the 1950s and 1960s Coid et al., , 1961 Sabin, 1955b) . Nonetheless, the reports were sufficient for two manufacturers to adopt this strain as the type I component for an IPV. The Brunenders-based IPVs produced by Glaxo laboratories (Beale, 2011; Evans, 1957) and SBL Sweden (from 1957 to 2004) (Böttiger, 1990) have been used successfully for decades. At present, however, the vast majority of commercially available IPVs have the Mahoney strain as the type I component. In Denmark, the Statens Serum Institute produces an IPV for the local population with a Brunhilde strain as the type I component (SSI, 2014) .
Today, to the best of our knowledge, no research has been conducted since the 1960s with the one-time prototype strain Brunhilde and its derivative Brunenders. Here, we aimed to characterize the Brunenders strain with respect to its neurovirulence, in vitro growth kinetics, in vitro antigenicity and genomic sequence, as well as using this viral sequence to understand the molecular basis for the reported neuroattenuation. As the world draws closer to the eradication of poliomyelitis, the incentive to move to attenuated strains as the basis for IPV is growing in momentum and has been actively stimulated by the World Health Organization (WHO, 2002) . The use of WT PVs as a basis for IPV would pose a biosafety threat in an eradication setting in the event of accidental escape from a manufacturing facility. Switching to attenuated strains would add additional biosafety to IPV manufacture and allow the production of such vaccines in lower-and middle-income countries. Currently, the Sabin strains are the most preferred and pursued candidates for novel IPVs based on attenuated strains. Nonetheless, the knowledge gained from Brunenders, which has already delivered as an IPV vaccine strain for decades, could potentially be applied to novel PV attenuation strategies.
RESULTS AND DISCUSSION

Brunenders is attenuated compared with WT polioviruses
To confirm the described attenuation of Brunenders, we determined and compared the strain's neurovirulence to other type 1 PVs in a CD155 transgenic mouse model (Koike et al., 1991) . When administered intracerebrally (i.c.), Brunenders required approximately 1000-fold more infectious units (TCID 50 ) to induce paralysis or death in 50% of the mice (PLD 50 ) when compared with the WT Mahoney and Brunhilde strains (Table 1) . This difference in virulence was roughly 100-fold when administered intramuscularly (i.m.) or intraperitoneally (i.p.). Nonetheless, Brunenders was at least 100-fold more virulent than Sabin 1, the oral vaccine strain, when administered i.c.
Brunenders displays in vitro growth kinetics comparable to other type 1 PVs
To determine whether the in vivo attenuation influenced in vitro growth kinetics, the replication curve of Brunenders was studied at physiological temperature (37 uC) and at low temperature (30 uC). It is known that attenuated viruses show impaired growth at higher temperatures (Bouchard et al., 1995) , but it is not clear whether their replication is affected at lower temperatures. In the case of Sabin strains, this is relevant for manufacturing, as the recommended temperature for propagation to minimize reversion is below 35 uC. Nine independent infections were performed in PER.C6 cells at an m.o.i. of 2 and cell density of 1|10 7 cells ml 21 (Fig. 1a) . Brunenders reached its maximum titre of 9-10 TCID 50 ml 21 by 24 and 8 h at 30 and 37 uC, respectively. These growth curves were compared to those of other PVs within the serotype (Fig. 1b) . The four PVs used (Mahoney, Brunenders, Brunhilde and Sabin 1) demonstrated almost identical growth curves at both 30 and 37 uC, and maximum titres and infection time to reach these were similar for all strains. This indicated that growth at low and physiological temperatures was similar for both parental (Brunhilde and Mahoney) and derived attenuated (Brunenders and Sabin 1) strains. These results are in line with previously published data with respect to titres and D-antigen production of PV strains on a PER.C6 platform, and also at a larger scale in 2 l bioreactors (Sanders et al., 2013) .
Temperature sensitivity at high temperatures (39-40 uC) compared with physiological temperature is often used as a measure of attenuation for Sabin (and other attenuated) strains. In line with this, Brunenders did indeed show slower growth kinetics and lower maximum yield (*1 log lower) at 39.5 uC compared with 37 uC (data not shown) in HeLaR19, L20B and HEK293 (a cell line that resembles the PER.C6 cell line) cells.
Mahoney and Brunenders show similar in vitro antigenicity
To ascertain the antigenicity of Mahoney and Brunenders, an in vitro D-antigen ELISA was performed to quantify an immunorelevant epitope in antigenic site 1. Fig. 2 for Brunenders and Mahoney, respectively. The difference in D-antigen content between the two strains was not significant using Student's t-test (P50.33). These results indicated that Mahoney and Brunenders are antigenically similar for the epitope measured in this D-antigen ELISA, which lies in antigenic site 1.
Genetic characterization of Brunenders
Having established the phenotype of the Brunenders compared to other type I strains, we proceeded to determine the genotype underlying these traits. With the obtained sequence data, an alignment of the known antigenic sites of the four PV1 strains was made (Table 2) . In general, all PV1 strains showed high sequence similarity in the antigenic regions, which is corroborated by the cross-protection observed within a given PV serotype. Brunenders and Mahoney shared the highest similarity with respect to amino acid sequence of the antigenic sites, with only one amino acid difference in antigenic site 1. Despite having an amino acid difference in site 1, the in vitro D-antigen ELISA, which uses a mAb directed to antigenic site 1, showed no difference in quantification of in vitro D-antigen content between Brunenders and Mahoney (Fig. 2) . The high sequence similarity in all antigenic sites and the similar in vitro D-antigen content for antigenic site 1 (Fig. 2) , together with the successful use of Brunenders as a vaccine strain in the field, suggest that a similar humoral immune response may be elicited compared with that against Mahoney. However, this will need to be shown by screening and comparison of sera from Brunenders versus Mahoney-based IPV recipients.
Brunenders differed in two amino acid positions from its derivative strain, Brunhilde. Sabin 1 showed the most divergent antigenic sequence, differing at five and six positions compared with Brunenders and Mahoney, respectively. These differences were in three of the four known antigenic sites (Martín et al., 2003; Minor, 1986; Minor et al., 1986) .
To potentially elucidate the molecular determinants of the attenuated phenotype, the sequenced viral genome of the Brunenders strain was aligned with the available Brunhilde sequence. A total of 31 nucleotide differences were observed, which are depicted schematically in Fig. 3 (a) and described in Table 3 . Overall sequence identity between Brunhilde and Brunenders was 99.6 %, which is in the range of the sequence identity between Mahoney and Sabin 1 (99.2 %; Fig. 3a) .
Three of the nucleotide differences were located in the 59 UTR, specifically in domains II and IV of the internal ribosomal entry site (IRES). Disruption of the secondary structure of this highly ordered RNA element exerts a direct effect on its function in translation of the viral polyprotein, as is the case for the three Sabin strains where a mutation in domain V of the IRES has been implicated to play a major role in their attenuation . However, upon careful analysis of the IRES mutations found here, it was unclear how they would influence the attenuation observed with Brunenders compared with Brunhilde. An alignment of a panel of PV IRESs of all serotypes ( Fig. 3b) revealed that the IRES mutation located in domain II (nt 146) was unique to Brunenders and conserved in all other PVs. Domain II has been described to display dual functionality, affecting translation as well as RNA replication, and previous research inducing different mutations in stem-loop II of the IRES has shown host-specific defects in translation (Nicholson et al., 1991; Shiroki et al., 1997) . However, the nt 146 mutation is Characterization of Brunenders located at the apex of stem-loop II and did not form a base pair with other nucleotides in the IRES, nor did it result in changes in secondary RNA structure or free energy (DG) (Fig. 3c) . The other IRES mutations located in domain IV (nt 388 and 416) were conserved among all strains except for Brunhilde (Fig. 3b) . These nucleotide differences also did not alter the predicted secondary RNA structure or decrease the thermostability (DG) of domain IV for Brunenders (data not shown), and therefore are unlikely to play a role in the observed attenuation.
The capsid region contained 18 nucleotide differences of which eight resulted in an amino acid substitution (Fig. 3a, Table 3 ). Some of the known attenuating mutations in the Sabin 1, CHAT and Cox strains, all attenuated derivatives of Mahoney, are also found in the capsid region (Martín & Minor, 2002; Pliaka et al., 2012) . In particular, mutation in aa 138 of VP2 (VP2-138) and VP2-142, which were also observed here, has been implicated to play a role in the attenuation of the CHAT and Cox strains. VP2-138, a threonine in Brunenders and CHAT, mutates to serine in a CHAT vaccine-associated paralytic poliomyelitis isolate, and mutation in VP2-142 is thought to affect viral entry, as this residue is located on the south rim of the canyon in a region that interacts with the cellular receptor (Belnap et al., 2000; He et al., 2003) .
Other amino acid substitutions observed here were VP1-222, which is also located on the south rim of the canyon close to the receptor-binding site and forms part of antigenic site 2A; VP2-168, which is located in antigenic site 2B; and VP1-43, located in the inner capsid surface. Furthermore, VP1-222 and VP2-138 have been reported to be involved in receptor binding (He et al., 2003) . Interestingly, three of the capsid mutations observed here (VP2-142, VP2-168 and VP1-43) have also been reported upon passaging of Sabin 1 in neuroblastoma cells to make S11, a persistent mutant that showed a non-lytic phenotype in vitro (Borzakian et al., 1993) . Coincidentally, these authors also observed 31 mutations between the Sabin 1 and S11 strains, of which 18 were in the capsid. Furthermore, all but one of the amino acid substitutions were found in the capsid proteins, and the authors hypothesized that these mutations may play a role in altered cell tropism. The capsid mutations observed here in Brunenders may contribute similarly to attenuation by alterations in cell/host tropism, as well as by hampering capsid stability, receptor binding, uncoating and/or release of RNA.
Altogether 10 nucleotide differences, all synonymous, were observed in the non-structural proteins (2A, 2C, 3B, 3C and 3D proteins; Fig. 3a , Table 2 ). One cannot ignore the potential role of silent mutations with respect to RNA structure. Nonetheless, none of the nucleotide differences was observed in known structural functional RNA elements, such as the cre element in 2C (Rieder et al., 2000) or the a and b domains in 3D (Song et al., 2012) , or in the 39 UTR. Therefore, their role in Brunenders attenuation may be less prominent. Remarkably, one of the silent mutations reported upon passage of Sabin 1 to S11 (Borzakian et al., 1993) was also observed here in Brunenders in the 2A protein (nt 3845 in Table 3 , which corresponds to nt 3481 in Sabin 1), where the authors also speculated that the observed silent mutations may play a role in alteration of RNA secondary structure.
To the best of our knowledge, the remainder of the silent mutations in the Brunenders non-structural proteins have not been reported elsewhere in the literature.
The sequencing results suggest strongly that the mutations in the capsid proteins play the most prominent role in Brunenders attenuation, given that all the amino acid changes between Brunhilde and Brunenders lay within these proteins. To confirm this, we constructed a chimaeric virus where the Brunenders capsid was exchanged with the Mahoney capsid. Interestingly, the chimaeric virus did not display the attenuated phenotype allocated to Brunenders. The PLD 50 values were restored to 3. (Table 1) . Thus, the capsid exchange increased neurovirulence 100-1000-fold, which provides further evidence that Brunenders attenuation is most likely induced by the mutations in this region. However, one cannot exclude the possibility that reversion of neurovirulence may be caused by the intrinsic virulence of the Mahoney capsid, rather than the loss of attenuation due to the mutations in the capsid of the Brunenders strain. Therefore, more research is required to pinpoint the contribution of each mutation to the attenuated phenotype observed with Brunenders.
CONCLUDING REMARKS
Mahoney is indisputably the most extensively studied member of the (wild)-type I PVs; it has enjoyed a career as the model PV in fundamental research and as Salk's strain of choice for his vaccine (Salk, 1953) . Research on the once-time prototype type I PV Brunhilde and its derivative Brunenders is scarce and historic, despite the fact that these two strains have been used as IPV strains, and that Brunhilde is still being used today in the Danish IPV. We have confirmed the historic reports of the attenuation of Brunenders, whilst the growth kinetics and sequence of antigenic sites were not affected compared with Mahoney. In fact, the in vitro antigenicity measured here, in an assay typically used for IPV vaccine dosing, was similar for Mahoney and Brunenders, which is in agreement with the successful use of a Brunenders-based IPV in Sweden and the UK from the 1950s onwards. The attenuation observed compared with Mahoney attests to the lobby for this safer IPV strain in the 1950s. In retrospect, the inclusion of Brunenders in the manufacture of IPV might have averted the tragedy of the Cutter incident and provides a valuable lesson on the inclusion of attenuated virus strains as manufacturing seed virus. We have demonstrated here that Brunenders is a neuroattenuated strain that also portrays excellent properties required for the production of potent IPV vaccine. Today, the discussion on exchanging the virulent WT strains as the basis for IPV continues as the world draws closer to eradication of poliomyelitis. Novel attenuated IPV vaccine strains will allow higher biosafety during vaccine manufacturing and lower the risk of outbreaks in the event of accidental escape from a production facility.
Interestingly, Enders and Sabin used a similar empirical approach to attenuate PVs via serial passage of a virulent strain in vitro and in vivo. However, they obtained strains that differed in their degree of attenuation. In contrast to the brief description of Brunenders' derivation and characterization (Enders et al., 1952) , Sabin concisely described the generation and testing of his strains for loss of neurovirulence, first in monkeys and later on in human volunteers (Sabin, 1955a, b; 1957; Sabin & Boulger, 1973) . The Mahoney strain in particular was extensively passaged in order to obtain Sabin 1, encompassing approximately 75 passages in monkeys and primary monkey kidney cells and including multiple plaque purifications and clonal selection steps along the process (Sabin & Boulger, 1973) . This is in contrast to the relatively simple derivation of Brunenders where the Brunhilde strain was subjected to only 12 subsequent passages in suspensions of human embryonic skin muscle cell cultures. The mutations responsible for the attenuation of Sabin strains have also been studied extensively (Bouchard et al., 1995; Macadam et al., 1993; Minor et al., 1993; Ren et al., 1991; Westrop et al., 1989) , where mutations in the capsid and in the 59 UTR contribute to attenuation for Sabin 1. The more extensive passaging could explain the higher degree of attenuation observed with Sabin 1 versus Mahoney compared with Brunenders versus Brunhilde, as well as the differences in the specific mutations contributing to the attenuated phenotype of those two strains via different molecular mechanisms.
In a trivalent, inactivated formulation, Sabin-based IPVs have shown promising immunogenicity in clinical studies as inactivated immunogens (Verdijk et al., 2014) . However, these data are not as extensive as the proven immunogenicity of Brunenders IPV by decades of use in the field. Nonetheless, Brunenders is still more virulent than the Sabin 1 strain, and would therefore not suffice as a safer alternative, despite the similarity to Mahoney with respect to antigenicity. Understanding the attenuation of Brunenders, which presumably stems from mutations in the capsid region, may provide additional insights for the generation of novel, further-attenuated IPV strains, with no compromise of WT strain antigenicity.
METHODS
Viruses and cell culture. The Brunenders, Sabin 1 and Mahoney strains were kindly provided by or purchased from Crucell Sweden (SBL), the National Institute for Biological Standards and Control, and the European Virus Archive, respectively. The Brunhilde and Brunenders-Mahoney P1 chimaera viruses were obtained by transfection of viral RNA generated from a plasmid containing the viral genome sequence carrying a phage T7 RNA polymerase promoter at the 59 end (van der Werf et al., 1986) . These plasmids were generated at Genscript and the sequences derived from public databases (Brunhilde GenBank accession number: AY560657) and in-house sequencing of the Brunenders and Mahoney strains.
PER.C6 cells were maintained in suspension in Permexcis medium (Lonza) and supplemented with 4 mM L-glutamine (Life Technologies) at 37 uC and 10 % CO 2 . One-step growth curves were performed in shaker flasks with a volume of 10 ml at a cell density of 1|10 7 ml 21 and inoculated with an m.o.i. of 1-2 TCID 50 per cell. Infections were incubated at either 30 or 37 uC and harvested at various time points post-inoculation. Titrations by TCID 50 assay and D-antigen ELISA of viral harvests were performed as described previously (Sanders et al., 2013) .
The D-antigen ELISA was performed at Bilthoven Biologics (previously Netherlands Vaccine Institute) using the immunochemical method described in the European Pharmacopoeia: 0214. Briefly, coating of 96-multiwell plates was achieved using type 1-specific bovine anti-PV antiserum (BBio) and the plates were then incubated overnight at room temperature. The next day, after washing and blocking steps, the plates were incubated with the virus sample for 1 h at 37 uC. After washing, the plates were incubated with type 1-specific mouse anti-PV mAbs, binding to antigenic site 1, for 1 h at 37 uC. The plates were then washed and incubated with sheep anti-mouse Ig (BBio), labelled with HRP (GE Healthcare), for 1 h at 37 uC. The plates were washed and substrate solution (SureBlue TMB 1) was added, after which the reaction was stopped using 2 M H 2 SO 4 (Merck) after 10 min of incubation. A four-parameter logistic model was used for calculation of the D-antigen concentration.
Sequencing of Brunenders. Viral RNA was isolated from a Brunenders harvest using a QIAamp Viral RNA Isolation kit (Qiagen) according to the manufacturer's protocol. The viral RNA was subsequently subjected to reverse transcription (RT) to produce cDNA with a Superscript III kit (Life Technologies). Priming was done using random hexamers as well as a specific RT primer. PCR of cDNA was performed with various primer pairs to amplify the viral cDNA. To determine the utmost 59 part of the virus, 59 RACE (Life Technologies) was used, according to the manufacturer's protocol. The resulting PCR fragments were sequenced by Sanger sequencing at BaseClear BV. All primers (except the random hexamers and anchor abridged primer for 59 RACE) were designed based on the Brunhilde sequence (GenBank accession no. AY560657) and are listed in Table 4 .
Neurovirulence assay in CD155 transgenic mice. All mice used were maintained under specific-pathogen-free conditions and animal experiments were performed in strict compliance with guidelines established by the Institutional Animal Care and Use Committee of Stony Brook University.
Groups of two to six CD155 transgenic mice were inoculated with a given amount of virus ranging from 10 2 to 10 8 TCID 50 per mouse. Virus was administered i.c. (30 ml per mouse), i.m. (50 ml per mouse) or i.p. (100 ml per mouse). Mice were examined daily for 21 days after inoculation for paralysis. The virus titre that induced paralysis or death in 50 % of the mice (PLD 50 ) was calculated by the method of Reed & Muench (1938) . Dilutions tested per virus, the number of mice per dilution group and the rate of paralysis/death observed per group are given in Supplementary Table S1, available in the online Supplementary Material.
RNA secondary structure prediction. For the prediction of RNA secondary structures of the IRES domains II and IV of Brunenders and Brunhilde, the MFOLD program was used (http://mfold.rna. albany.edu/?q5mfold/RNA-Folding-Form) (Zuker, 2003) . 
